Tech Company Financing Transactions
Primrose Bio Funding Round
On 7/15/2026, Primrose Bio secured $2 million in funding from National Institutes of Health.
Transaction Overview
Company Name
Announced On
7/15/2026
Transaction Type
Debt
Amount
$2,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Primrose Bio will use its proprietary ultra-high-throughput platform to screen billions of sequences, validate in cell models and apply proprietary AI-design optimization to create licensable sequence elements for DNA- and RNA-based medicines.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10790 Roselle St
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Primrose Bio offers radically new products and tools that unlock unexplored possibilities for the discovery, development, and manufacturing of new molecules. Our mission is to enable the development of innovative therapeutics, vaccines and ingredients to advance global health.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Drew Burch
Chief Financial Officer
Simon Latimer
Controller
Marc Ayres
President
Diane Retallack
Vice President
Jeff Allen
VP - Bus. Development
Louis Cantolupo
VP - Engineering
Russell Coleman
VP - Operations
Bill Colby
VP - Product Management
Jennifer Wittbold
Browse more venture capital transactions:
Prev: 7/15/2026: AdvanCell venture capital transaction
Next: 7/16/2026: Silicon Microgravity venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs